Posts tagged “Biotech & Life Science”
SoBran BioScience, a 500-employee contract research organization based in Fairfax, Va., will open a new animal research facility this summer in Greensboro, providing a bio-boost for the Triad.
The former CEO and CFO of Salix Pharmaceuticals, which was sold to Valeant Pharmaceuticals for more than $11 billion a year ago, are being investigated by the SEC, according to the Reuters news service.
Chimerix, which has a contract potentially worth more than $400 million in the development of a first vaccine targeting smallpox, reports progress in development of an antiviral. In recent tests, its brincidofovir successfully treated 100 percent of animals infected with rabbitpox.
Talk about a sell-off. Early Monday, Triangle-based Biocryst disclosed news that a drug candidate targeting a rare genetic condition had failed. The news set off an immediate plunge in its share price, triggered a Wall Street downgrade - and a possible lawsuit.
Novan Therapeutics, a high-profile emerging pharmaceutical firm backed by big-name investors in the Triangle with a focus on developing new dermatology treatments, has a new chairman. But his name is a familiar one. Another well-known name leaves the board in the shuffle.
In today's Bulldog wrapup of technology and life science news: Twitter cracks down on terror; J&J pursues diabetes cure; McKinney loses major account; LinkedIn's shares plunge 44 percent; and Merck sales miss estimates.
Healthcare workers are hardly immune from the threat of a jobless future as being explored in this week's Emerging Issues Forum "Future Work" conference. But as one of speakers explains opportunities will remain available for humans in healthcare.
More than 50 emerging life science startups will have the chance to make their case for investment to possible backers at the CED's Life Science Conference next month. The CED announced its selections early Monday.
WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.
"ChemChina has demonstrated a strategic and pragmatic approach with other investments the company has made in U.S. operations," says N.C. Biotechnology Center exec. "We expect that as a result, it will continue to value the advantages provided within North Carolina, as the largest cluster of high-tech agriculture in the world."
The North Carolina Biotechnology Center awarded more than $1.63 million in 18 loans and grants to propel the life science sector statewide during the last quarter of 2015. Among the total is almost $600,000 awarded through the new Biotechnology Innovation Grant program.
In observance of Feb. 4 as "World Cancer Day," Terry Murdock, the head of the Oncology Center of Excellence at Quintiles, writes in a blog that "there is much to celebrate" this year in the fight against cancer.
Shares in Heat Biologics plunged 25 percent Wednesday after the company disclosed that the FDA put a "partial clinical hold" on a recently launched clinical trial. However, Heat says its "timelines" for the treatment "remain materially unchanged."
British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.
After saying "no" to a $46.5 billion bid from Monsanto, the board of crop giant Syngenta has said "yes" to a $43 billion acquisition by Chinese chemical giant ChemChina. Syngenta has a big presence in RTP.